A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants With Gastroparesis
While NG101 did not meet statistical significance in its primary end point for reducing nausea severity, it demonstrated a favorable safety profile and significant improvement in some secondary end points. Further study is needed to determine whether NG101 is an effective treatment for patients with idiopathic gastroparesis.
Authors
- Pankaj J. Pasricha (ORCID: https://orcid.org/0000-0002-8727-683X)
- Judy Nee (ORCID: https://orcid.org/0000-0002-9437-4163)
- Madison L. Simons (ORCID: https://orcid.org/0000-0002-5042-2725)
- Anthony J Lembo (ORCID: https://orcid.org/0000-0002-4479-1188)
- J. Trig Brown
- Michael Cline
- Matthew Hoscheit
- Scott Gabbard (ORCID: https://orcid.org/0000-0002-8915-3016)
- Samita Garg (ORCID: https://orcid.org/0009-0002-2493-1881)
- Cyril De Colle
- James A. MacDougall
- Jack Loesch (ORCID: https://orcid.org/0009-0005-4956-1612)
- Eyad Hamza
Institutions
- Beth Israel Deaconess Medical Center (US)
- Cleveland Clinic (US)
- Mayo Clinic in Arizona (US)
- Institute of Neurobiology (BG)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.14309/ajg.0000000000003534
- Primary Topic
- Complementary and Alternative Medicine Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00